You are here

  • Home
  • Archive
  • Volume 11, Issue 4
  • Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen

Article info

Article menu

Download PDFPDF

Immunotherapy biomarkers
Original research
Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen

Authors

  • Pu Chen Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Disease, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Peking University People's Hospital, Beijing, China PubMed articlesGoogle scholar articles
  • Dongbo Chen Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Disease, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Peking University People's Hospital, Beijing, China PubMed articlesGoogle scholar articles
  • Dechao Bu Research Center for Ubiquitous Computing Systems, Institute of Computing Technology, Chinese Academy of Sciences, Beijing, China PubMed articlesGoogle scholar articles
  • Jie Gao Department of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China PubMed articlesGoogle scholar articles
  • Wanying Qin Laboratory of Hepatobiliary and Pancreatic Surgery, Guilin Medical University Affiliated Hospital, Guilin, Guangxi, China PubMed articlesGoogle scholar articles
  • Kangjian Deng Laboratory of Hepatobiliary and Pancreatic Surgery, Guilin Medical University Affiliated Hospital, Guilin, Guangxi, China PubMed articlesGoogle scholar articles
  • Liying Ren Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Disease, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Peking University People's Hospital, Beijing, China PubMed articlesGoogle scholar articles
  • Shaoping She Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Disease, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Peking University People's Hospital, Beijing, China PubMed articlesGoogle scholar articles
  • Wentao Xu Laboratory of Hepatobiliary and Pancreatic Surgery, Guilin Medical University Affiliated Hospital, Guilin, Guangxi, China PubMed articlesGoogle scholar articles
  • Yao Yang Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Disease, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Peking University People's Hospital, Beijing, China PubMed articlesGoogle scholar articles
  • Xingwang Xie Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Disease, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Peking University People's Hospital, Beijing, ChinaCorregene Biotechnology Co., Ltd, Beijing, China PubMed articlesGoogle scholar articles
  • Weijia Liao Laboratory of Hepatobiliary and Pancreatic Surgery, Guilin Medical University Affiliated Hospital, Guilin, Guangxi, China PubMed articlesGoogle scholar articles
  • Hongsong Chen Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Disease, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Peking University People's Hospital, Beijing, China PubMed articlesGoogle scholar articles

Citation

Chen P, Chen D, Bu D, et al
Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen
Journal for ImmunoTherapy of Cancer 2023;11:e006334. doi: 10.1136/jitc-2022-006334
Online issue publication 
December 07, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.